Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AZTR | US
-0.01
-3.27%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.20
0.20
0.21
0.20
Azitra Inc a pre-clinical biopharmaceutical company focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12 a genetically modified strain of S. epidermidis for treating Netherton syndrome a skin disease; ATR-04 a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01 an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris a skin disease. The company was incorporated in 2014 and is based in Branford Connecticut.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
78.2%1 month
87.8%3 months
155.4%6 months
129.7%0.01
-
2.42
0.42
0.19
-0.39
10.02
-
-10.12M
1.56M
1.56M
-
-35.47K
-
-95.60
-222.30
0.78
3.18
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.04
Range1M
0.07
Range3M
0.28
Rel. volume
0.69
Price X volume
73.02K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals Inc | SNOA | Drug Manufacturers-Specialty & Generic | 1.09 | 1.46M | -4.39% | n/a | 8.44% |
| SHPH | SHPH | Drug Manufacturers-Specialty & Generic | 0.4842 | 1.43M | 6.65% | n/a | 144.16% |
| International Stem Cell Corporation | ISCO | Biotechnology | 0.17 | 1.36M | n/a | 0.00% | |
| Premier Biomedical Inc | BIEI | Drug Manufacturers-Specialty & Generic | 0.0012 | 1.32M | 9.09% | n/a | -22.64% |
| RedHill Biopharma Ltd | RDHL | Biotechnology | 1.02 | 1.31M | -0.97% | n/a | 65.80% |
| Soligenix Inc | SNGX | Biotechnology | 0.4225 | 963.48K | -4.69% | n/a | 84.28% |
| Phio Pharmaceuticals Corp | PHIO | Biotechnology | 1.09 | 938.19K | 2.83% | n/a | 0.00% |
| Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 0.2088 | 906.60K | -1.74% | n/a | 4.18% |
| Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.1 | 810.46K | n/a | 5.50% | |
| CARM | CARM | Biotechnology | 0.019 | 789.35K | 18900.00% | n/a | 1044.17% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.39 | 0.53 | Cheaper |
| Ent. to Revenue | 10.02 | 3,967.00 | Cheaper |
| PE Ratio | 0.01 | 41.03 | Cheaper |
| Price to Book | 2.42 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 155.36 | 72.80 | Riskier |
| Debt to Equity | 0.42 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 1.56M | 3.66B | Emerging |